As a result, pharmacological inhibition of Src would increase Cad11/gp130/Stat3 levels in tumors with high Src activity, hence increase, rather than decrease, the metastatic ability of the tumor, leading to a deterioration in clinical outcome. This evidence concerns the gene SRC and neoplasm.